Format

Send to

Choose Destination
J Infect Dis. 2014 Jun 1;209(11):1700-4. doi: 10.1093/infdis/jit827. Epub 2013 Dec 23.

IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.

Author information

1
Laboratory of Immunoregulation/National Institute of Allergy and Infectious Diseases/National Institutes of Health, Bethesda, Maryland.

Abstract

Response to pegylated interferon-alpha and ribavirin (IFN-α/RBV) treatment for chronic hepatitis C virus (HCV) infection is influenced by host genetic factors, but their role for IFN-α-free, direct-acting antiviral (DAA) regimens is unclear. An exonic deletion allele (IFNL4-ΔG) bolsters the established association with IFN-α/RBV therapy treatment outcome of another IFNL4 variant, rs12979860, which is located upstream of IFNL3 (IL28B). We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-ΔG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-λ4 in IFN-α-free DAA therapies.

KEYWORDS:

DAA therapy; IFNL4; IL28B; SVR; haplotype; hepatitis C virus; pharmacokinetics; relapse; viral kinetics

PMID:
24367041
PMCID:
PMC4017364
DOI:
10.1093/infdis/jit827
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center